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DObjective: Vasoconstrictors such as norepinephrine and vasopressin are commonly used to raise the blood pres-
sure during myocardial revascularization. The internal thoracic artery is commonly used for coronary artery graft-
ing because of its long-term patency. However, the internal thoracic artery is a living conduit that responds to
vasoactive substances. The objective of this study was to measure change in internal thoracic arterial flow after
infusion of norepinephrine or vasopressin.
Methods: Forty-one patients undergoing elective off-pump coronary artery bypass grafting participated in this
study. After the median sternotomy, the left internal thoracic artery was dissected with a pedicle and grafted to
the left anterior descending artery. After all anastomoses were performed and hemodynamic parameters were sta-
ble, the grafted internal thoracic arterial blood flowwas measured by transit time flowmeter on the distal portion of
the graft as a baseline. Norepinephrine or vasopressin was then infused until mean arterial pressure was increased
to 20% of baseline. Graft flow and hemodynamic variables were measured when mean arterial pressure reached
the intended level.
Results: Baseline grafted internal thoracic arterial flows were similar (norepinephrine 57.1  17.7 mL min1,
vasopressin 66.0  34.3 mL min1). With norepinephrine, flow increased significantly relative to baseline
(77.2  31.0 mL min1); with vasopressin, it remained unchanged (68.3  37.0 mL min1).
Conclusions: For patients needing vasopressor support after coronary artery bypass grafting, norepinephrine ap-
peared superior to vasopressin because of increased internal thoracic arterial flow. (J Thorac Cardiovasc Surg
2011;141:151-4)Vasoactive agents, particularly vasoconstrictors such as nor-
epinephrine or vasopressin, are commonly used in the peri-
operative period to elevate the mean arterial pressure in
patients undergoing myocardial revascularization. The inter-
nal thoracic artery (ITA) is commonly used for coronary
artery bypass grafting because of its long-term patency rela-
tive to standard saphenous vein grafts.1 The ITA, however,
is a living conduit that is responsive to vasoactive sub-
stances.2-8 Although beneficial effects of vasopressive
therapy with a vasoconstrictor have been demonstrated,8,9
it has been suggested that the administration of
vasoconstrictors to elevate the coronary perfusion pressure
may lead to a decrease in ITA blood flow.7,9
It is important to determine whether the ITA graft flow
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The Journal of Thoracic and Carevascularization. The objective of this studywas to compare
ITA flows after the use of norepinephrine and vasopressin.MATERIALS AND METHODS
This study was approved by the institutional review board, and all pa-
tients provided written, informed consent. Patients with peripheral vascular
disease, chronic significant arrhythmia, left ventricular ejection fraction less
than 35%, or mitral regurgitation more than grade 2 were excluded from the
study. Patients who were receiving inotropic agents were also excluded.
Forty-one patients undergoing elective off-pump coronary artery bypass
grafting participated in this study. Before surgery, the patients were ran-
domly allocated to receive norepinephrine or vasopressin. Norepinephrine
and vasopressin infusions were prepared by another researcher not involved
in the patient care. Both the surgeon and the attending anesthesiologist were
blinded to the allocation of patients to receive norepinephrine or vasopres-
sin. There were no significant differences in demographic characteristics
between the groups. The demographic data are presented in Table 1.
Preoperative medications were continued until the morning of surgery.
All patients were medicated in advance with intramuscular morphine
(0.05–0.1 mg kg1 ). Five electrocardiographic leads were placed, and leads
II andV5were continuouslymonitored. The arterial pressure wasmonitored
with a radial artery catheter placed in the dominant hand. A pulmonary ar-
terial catheter (Swan-Ganz CCOmbo-CC0/SvO2, Edwards Lifesciences
LLC, Irvine, Calif) was inserted in the right internal jugular vein to monitor
several cardiac performance parameters continuously, including central ve-
nous pressure (CVP), pulmonary artery pressure (PAP), cardiac output, and
right ventricular volumetric parameters. All patients then received general
anesthesia consisting of sufentanil and midazolam and supplemented by
sevoflurane in an oxygen and air mixture. Vecuronium bromide was usedrdiovascular Surgery c Volume 141, Number 1 151
Abbreviations and Acronyms
CVP ¼ central venous pressure
ITA ¼ internal thoracic artery
MAP ¼ mean arterial pressure
PAP ¼ pulmonary arterial pressure
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Dfor muscle relaxation. Transesophageal echocardiography was used to mon-
itor global and regional left ventricular function from the short-axis trans-
gastric view.
After median sternotomy, the left ITA was dissected with a pedicle. To
minimize vasospasm, papaverine was injected into the adventitia of the ITA.
After the ITA dissection, heparin was injected intravenously. In all cases the
ITA was grafted to the distal left anterior descending coronary artery.
After all the anastomoses had been performed, the protamine infusion
was finished, and the patient was in hemodynamically stable condition,
baseline grafted ITA blood flowwas measured with a transit-time flowmeter
(flash probe; Transonic Systems Inc, Ithaca, NY) on the distal portion of the
graft body and hemodynamic data, including the cardiac index, heart rate,
mean arterial pressure (MAP), mean PAP, CVP, and pulmonary capillary
wedge pressure were collected.
After the procedure was completed, the continuous infusion of norepi-
nephrine or vasopressin was started. The concentrations of norepinephrine
(8 mg mL1) and vasopressin (0.2 U mL1) were chosen so that the starting
infusion volume was 10 mL h1. During the study, the drugs were titrated
(infusion increased by 10 mL h1 every 5–10 minutes) to maintain an ap-
proximately 20% increase in MAP according to an independent anesthesi-
ologist blinded to the type of drug that was administered. The graft flow
measurements and hemodynamic variables were repeated as described pre-
viously.
All data are expressed as mean SD or number of patients. Sample-size
calculation was performed according to the results of a preliminary study
under the following assumptions: an 80% power to detect a 10% difference
in the change of ITA graft blood from the baseline value and an a level of
.05. These assumptions generated an estimate of 16 patients in each group.
Demographic data were analyzed with the unpaired t test. Comparison of
means within the groups was performed with the paired t test. The changes
in the ITA graft blood flow and hemodynamic variables were compared be-
tween the groups with an unpaired t test. All analyses were conducted with
SPSS version 13.0 (SPSS Inc, an IBM Company, Chicago, Ill).RESULTS
In the norepinephrine group, the administration of norepi-
nephrine increased the MAP from 71.8  5.4 mm Hg to
85.8  6.2 mm Hg (P< .001) and the systemic vascular re-
sistance index from 2325.8  593.6 dyne $ s $ m2 $ cm5 to
2639.0 515.5 dyne $ s $m2 cm5 (P¼ .020) and decreased
the CVP from 6.7  1.8 mm Hg to 6.4  1.6 mm Hg
(P ¼ .031). No significant changes in the heart rate, mean
PAP, cardiac index, and peripheral vascular resistance index
were observed (Table 2).
In the vasopressin group, vasopressin infusion increased the
MAP from72.1 5.1mmHg to 86.1 5.5mmHg (P<.001)
and the systemic vascular resistance index from 2353.5 
711.9 dyne $ s $ m2 $ cm5 to 2643.0  662.0 dyne $ s $ m2
$ cm5 (P¼ .011) and decreased the peripheral vascular resis-
tance index from223.5 59.2 dyne $ s $m2 $ cm5 to 193.3152 The Journal of Thoracic and Cardiovascular Surg60.4 dyne $ s $m2 $ cm5 (P¼ .007). Therewere no significant
changes in heart rate, mean PAP, CVP, and cardiac index
(Table 2). There were no significant differences in hemody-
namic variables between the treatment groups.
The baseline grafted ITA flows were similar in the treat-
ment groups (norepinephrine 57.1 17.7 mLmin1 vs vaso-
pressin 66.0 34.3 mLmin1). In the norepinephrine group,
ITA flow increased from 57.1  17.7 mL min1 to 77.2 
31.0 mLmin1 (P¼ .015), whereas in the vasopressin group,
it remained unchanged (66.0  34.3 mL min1 vs 68.3 
37.0 mL min1; Table 2).
DISCUSSION
In this study, we found that the administration of norepi-
nephrine increased the blood flow of the grafted ITA. In con-
trast, the infusion of vasopressin did not induce any
significant change in the grafted ITA blood flow.
The ITA is ideally suited for coronary artery grafting. His-
tologically, the ITA is composed of a thin-walled media and
a well-formed internal elastic lamina. These properties may
be responsible for its long-term patency and low susceptibil-
ity to atherosclerosis relative to grafts from the saphenous
vein.10 The ITA, however, is a living conduit that reacts to
vasoactive drugs.2-8,10 Once the ITA has been grafted, flow
is influenced by the downstream resistance as well as by
the effects of endogenous or exogenous vasoconstrictors
on the ITA itself.5
Graft flow is dependent not only on the effects of vasoac-
tive drug on the conduit but also on the effects of vasoactive
drugs on the regional vasculature, coronary vasculature, or
a combination.7 Once anastomosed, the ITA functions as
an epicardial coronary artery and is subject to all the deter-
minants of coronary flow, such as heart rate, aortic pressure,
left ventricular pressure, and coronary vascular resistance.5
In addition, the ITA has been shown to be a dynamic conduit
capable of enlarging to meet the metabolic demands of its
coronary vascular bed.6,7 There is a report that Y-graft
blood flow is also significantly increased in response to
increased myocardial oxygen demand.11
Graft flow immediately after myocardial revascularization
has received less attention than long-term patency. It is in the
immediate postgraft period, however, that most hemody-
namic instability occurs.As theMAPdecreases, there is a dis-
proportionate reduction in arterial graft flow.8 Hypotension
should be corrected immediately by cessation of vasodilator
therapy or the addition of an appropriate vasoconstrictor. The
use of a vasoconstrictor to counteract the hypotension may
occasionally reduce the ITA blood flow as a result of graft
vessel vasoconstriction; however, restoration of a normal
MAP pressure is of more importance than the potential loss
of blood flow through the vasoconstriction.4,9
Norepinephrine is a potent a-adrenergic vasoconstrictor
and a relatively mild b-adrenergic agonist that has positive
inotropic and chronotropic effects. Whereas less thanery c January 2011
TABLE 1. Patient characteristics
Norepinephrine
(n ¼ 20)
Vasopressin
(n ¼ 21)
Age (y, mean  SD) 62.0  9.3 60.7  8.6
Sex (male/female ratio) 11:9 17:4
Weight (kg, mean  SD) 66.5  8.6 69.2  9.9
Height (cm, mean  SD) 162.0  9.4 166.6  7.5
Body surface area (m2, mean  SD) 1.7  0.1 1.8  0.1
There were no statistically significant differences between groups.
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tion, the usual infusion rates of greater than 3 mg/min elicit
peripheral vasoconstriction from a-adrenergic stimulation.12
The marked pressor effects are primarily due to increased
peripheral vascular resistance mediated through both the
a1 and a2 postsynaptic receptors. During the precise control
of cardiac output and blood pressure, which were maintained
at constant levels during drug infusion to isolate the effects
of the drug on the ITA conduit, norepinephrine did not alter
the ITA blood flow.6 Conversely, Jett and colleagues7 dem-
onstrated that norepinephrine increases the ITA blood flow,
with concomitant increase in the rate of left ventricular pres-
sure that represented an increase in myocardial oxygen con-
sumption. Their study is consistent with our results. It is
considered that norepinephrine increases the ITA graft blood
flow through increased myocardial oxygen demand and per-
fusion pressure.
Vasopressin, a hypothalamic hormone stored and released
by the neurohypophysis, has marked vasoconstrictor effect13
and has recently gained attention as a possible tool against
septic shock and vasodilation states associated with cardiac
anesthesia and surgery; therefore, it is also used during the
postgraft hypotensive state.2,14 Although some studies
have suggested that vasopressin improves vital organ
blood flow, including cerebral and coronary blood flow,
during cardiopulmonary resuscitation by increasing
perfusion pressure,15-18 the results of in vitro studies have
suggested that ITA is constricted by vasopressin.19 Thus va-
sopressin has been considered to provoke graft vesselTABLE 2. Hemodynamics and internal thoracic arterial flows after norep
Norepinep
Baseline
Heart rate (beats min1) 71.0  13.0
Mean arterial pressure (mm Hg) 71.8  5.4
Mean pulmonary arterial pressure (mm Hg) 17.4  2.9
Central venous pressure (mm Hg) 6.7  1.8
Resistance index (dyne $ s $ m2 $ cm5)
Systemic 2325.8  593.6
Pulmonary 195.6  72.6
Cardiac index (L [min m2]1 ) 2.4  0.6
Internal thoracic arterial flow (mL min1) 57.1  17.7
All values are expressed as mean  SD. *P< .05 versus baseline.
The Journal of Thoracic and Caspasm.9,19 Although vasopressin is known to be associated
with coronary vasoconstriction, few studies have been
conducted to evaluate its effects on ITA blood flow in
vivo.2,9 In this study, vasopressin infusion did not change
the grafted ITA blood flow, despite the increased
myocardial oxygen consumption. These results suggest
that ITA vasoconstriction caused by vasopressin infusion
could be more potent than that caused by norepinephrine
infusion.
In addition to information regarding the grafted ITA blood
flow, in this study vasopressin decreased the peripheral vas-
cular resistance index. To date, few studies have been con-
ducted to evaluate peripheral vascular resistance, and the
described effects of vasopressin on pulmonary vessels
have not been consistent.20-23 On the basis of the results of
this study and previous studies,21-23 we speculate that
vasopressin is favorable for treating low systemic vascular
resistance hypotension with pulmonary hypertension.
In addition to the effects of norepinephrine and vasopres-
sin on the ITA, there is ample reason to think that other fac-
tors may influence the graft flow. The ITA is a dynamic
coronary graft, whereas the saphenous vein graft is passive.
Measurement of saphenous vein graft flow thus might help
to shed light on the site of action in this study. In a previous
study,6 norepinephrine increased flows in both ITA and sa-
phenous vein grafts with similar patterns. In the cases of va-
sopressin, however, there has been no study regarding
saphenous vein graft flow.
It should be noted that this study has some limitations.
First, the transit-time Doppler probes used are accurate but
sensitive to differences in angle, which is sometimes difficult
to control when the heart and the lungs are moving. Because
operator-dependent measurement errors were possible, the
same operator measured the graft flow whenever possible,
and the operator was blinded to the allocation of the study
drug. Second, anesthetic agents, especially inhalational
agents, can induce grafted ITA vasodilation. To minimize
factors that affect vessel tone, anesthetic agents (narcotic
plus inhalational agent) were controlled throughout theinephrine and vasopressin
hrine Vasopressin
After drug Baseline After drug
71.7  12.8 69.9  11.4 68.9  11.6
85.8  6.2* 72.1  5.1 86.1  5.5*
17.3  2.4 17.9  5.0 17.5  5.5
6.4  1.6* 6.1  2.4 5.9  2.1
2639.0  515.5* 2353.5  711.9 2643.0  662.0*
199.1  72.6 223.5  59.2 193.3  60.4*
2.5  0.4 2.4  0.7 2.5  0.6
77.2  31.0* 66.0  34.3 68.3  37.0
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control of bleeding and hemodynamic stability had been
achieved. Third, doses of the vasoconstrictors were not eval-
uated in this study. The creative aspect of this study design
was that elevation of MAP to the intended level was consid-
ered as the pharmacodynamic end point. In previous studies
regarding graft blood flow change after drug administration,
infusion rates of study drugs were predetermined.3-7
Elevation of perfusion pressure was thus not achieved in
some studies.5-7 In this study, because the elevation of
MAP during vasoconstrictor infusion was considered as
the pharmacodynamic end point, only a starting dose was
selected and doses were escalated until the intended MAP
level had been achieved. The influence of doses of
vasoconstrictor on ITA grafts needs further investigation.CONCLUSIONS
Systemic hypotension is common during coronary revas-
cularization surgery. A vasoconstrictor is frequently needed
to correct the hypotension, despite grafted vessel constric-
tion. Thus the vascular reactivity of the ITA must be taken
into consideration when vasoconstrictors are used after
coronary revascularization. This study demonstrates that
for patients needing vasopressor support after coronary
revascularization, norepinephrine appears to be superior to
vasopressin because of the increase in ITA blood flow.References
1. Loop FD, Lytle BW, Cosgrove DM, Stewart RW, Goormastic M, Williams GW,
et al. Influence of the internal-mammary-artery graft on 10-year survival and other
cardiac events. N Engl J Med. 1986;314:1-6.
2. Novella S, Martı´nez AC, Paga´n RM, Herna´ndez M, Garcı´a-Sacrista´n A,
Gonza´lez-Pinto A, et al. Plasma levels and vascular effects of vasopressin
in patients undergoing coronary artery bypass grafting. Eur J Cardiothorac
Surg. 2007;32:69-76.
3. Na S, Oh YJ, Shim YH, Hong YW, Bang SO, Kwak YL. Effects of milrinone on
blood flow of the Y-graft composed with the radial and the internal thoracic artery
in patients with coronary artery disease. Eur J Cardiothorac Surg. 2006;30:324-8.
4. Lobato EB, Janelle GM, Urdaneta F, Martin TD. Comparison of milrinone versus
nitroglycerin, alone and in combination, on grafted internal mammary artery flow
after cardiopulmonary bypass: effects of alpha-adrenergic stimulation. J Cardio-
thorac Vasc Anesth. 2001;15:723-7.
5. Lobato EB, Urdaneta F, Martin TD, Gravenstein N. Effects of milrinone versus
epinephrine on grafted internal mammary artery flow after cardiopulmonary by-
pass. J Cardiothorac Vasc Anesth. 2000;14:9-11.154 The Journal of Thoracic and Cardiovascular Surg6. Gitter R, Anderson JM Jr, Jett GK. Influence of milrinone and norepinephrine on
blood flow in canine internal mammary artery grafts. Ann Thorac Surg. 1996;61:
1367-71.
7. Jett GK, Arcidi JM Jr, Dorsey LM, Hatcher CR Jr, Guyton RA. Vasoactive drug
effects on blood flow in internal mammary artery and saphenous vein grafts.
J Thorac Cardiovasc Surg. 1987;94:2-11.
8. Beavis RE, Mullany CJ, Cronin KD, Scott DA, Treagus BC, Zhikun Y, et al. An
experimental in vivo study of the canine internal mammary artery and its response
to vasoactive drugs. J Thorac Cardiovasc Surg. 1988;95:1059-66.
9. Rosenfeldt FL, He GW, Buxton BF, Angus JA. Pharmacology of coronary artery
bypass grafts. Ann Thorac Surg. 1999;67:878-88.
10. Janelle GM, Urdaneta F, Martin TD, Lobato EB. Effects of calcium chloride on
grafted internal mammary artery flow after cardiopulmonary bypass. J Cardio-
thorac Vasc Anesth. 2000;14:4-8.
11. He GW, Angus JA, Rosenfeldt FL. Reactivity of the canine isolated internal mam-
mary artery, saphenous vein, and coronary artery to constrictor and dilator sub-
stances: relevance to coronary bypass graft surgery. J Cardiovasc Pharmacol.
1988;12:12-22.
12. Jonathan M, David G. The autonomic nervous system. In: Miller RD, ed. Miller’s
anesthesia. 6th ed. Philadelphia: Elsevier; 2005:649.
13. Treschan TA, Peters J. The vasopressin system: physiology and clinical strategies.
Anesthesiology. 2006;105:599-612.
14. Sanjay OP, Kilpadi K, Prashanth P, Vincent V, Thejas BC. Use of arginine vaso-
pressin in the management of vasodilatory shock after CABG——a clinical trial.
Ann Card Anaesth. 2003;6:132-5.
15. Morris DC, Dereczyk BE, Grzybowski M, Martin GB, Rivers EP, Wortsman J,
et al. Vasopressin can increase coronary perfusion pressure during human cardio-
pulmonary resuscitation. Acad Emerg Med. 1997;4:878-83.
16. Wenzel V, Lindner KH, Prengel AW, Maier C, Voelckel W, Lurie KG, et al.
Vasopressin improves vital organ blood flow after prolonged cardiac arrest with
postcountershock pulseless electrical activity in pigs. Crit Care Med. 1999;27:
486-92.
17. Wenzel V, Lindner KH, Krismer AC, Miller EA, Voelckel WG, Lingnau W.
Repeated administration of vasopressin but not epinephrine maintains coronary
perfusion pressure after early and late administration during prolonged cardiopul-
monary resuscitation in pigs. Circulation. 1999;99:1379-84.
18. Johansson J, Gedeborg R, Rubertsson S. Vasopressin versus continuous adrena-
line during experimental cardiopulmonary resuscitation. Resuscitation. 2004;62:
61-9.
19. Wei W, Floten HS, He GW. Interaction between vasodilators and vasopressin in
internal mammary artery and clinical significance. Ann Thorac Surg. 2002;73:
516-22.
20. Mols P, Hallemans R, Van Kuyk M, Melot C, Lejeune P, Ham H, et al. Hemody-
namic effects of vasopressin, alone and in combination with nitroprusside, in
patients with liver cirrhosis and portal hypertension. Ann Surg. 1984;199:176-81.
21. Altintas E, Akkus N, Gen R, Helvaci MR, Sezgin O, Oguz D. Effects of terlipres-
sin on systolic pulmonary artery pressure of patients with liver cirrhosis: an
echocardiographic assessment. World J Gastroenterol. 2004;10:2278-80.
22. Evora PR, Pearson PJ, Schaff HV. Arginine vasopressin induces endothelium-
dependent vasodilatation of the pulmonary artery. V1-receptor-mediated produc-
tion of nitric oxide. Chest. 1993;103:1241-5.
23. Jeon Y, Ryu JH, Lim YJ, Kim CS, Bahk JH, Yoon SZ, et al. Comparative
hemodynamic effects of vasopressin and norepinephrine after milrinone-
induced hypotension in off-pump coronary artery bypass surgical patients. Eur
J Cardiothorac Surg. 2006;29:952-6.ery c January 2011
